<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03364985</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWP16001001</org_study_id>
    <nct_id>NCT03364985</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP16001 After Oral Administration in Healthy Male Volunteers</brief_title>
  <official_title>A Phase I, Randomized, Double-blind, Placebo- and Active-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of DWP16001 Following Oral Administration in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose block-randomized, double-blind, placebo- and active-controlled, single and
      multiple dosing, dose-escalation clinical phase 1 trial to investigate the safety,
      tolerability, pharmacokinetics and pharmacodynamics of DWP16001 after oral administration in
      healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and percentage of Participants With Adverse Events (AE)</measure>
    <time_frame>Day -2(Randomization) to Day 8~12(Post-study visit) in single ascending dose or Day-3d to Day 22~ (Post-study visit)</time_frame>
    <description>All AE standardized using MedDRA was assessed by investigator using the protocol defined grading system. Intensity was categorized as mild, moderate and severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and percentage of Participants With Adverse Drug Reactions (ADR)</measure>
    <time_frame>Day -2(Randomization) to Day 8~12(Post-study visit) in single ascending dose or Day-3d to Day 22~ (Post-study visit)</time_frame>
    <description>An adverse drug reaction (ADR) is an injury caused by taking an investigational product</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Vital Sign findings</measure>
    <time_frame>Day -2(Randomization) to Day 8~12(Post-study visit) in single ascending dose or Day-3d to Day 22~ (Post-study visit)</time_frame>
    <description>Blood pressure, pulse and body temperature were tested. The Average, Median, Standard Deviation, Min, Max values will be calculated to assess the safety/tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Electrocardiogram(12-lead ECG) findings</measure>
    <time_frame>Day -2(Randomization) to Day 8~12(Post-study visit) in single ascending dose or Day-3d to Day 22~ (Post-study visit)</time_frame>
    <description>Ventricular rate, RR interval, PR interval, QRS duration, QTcB and QTcF were recorded. The results of 12-lead ECG will be categorized Normal/Abnormal NCS(No clinically significant)/Abnormal CS(clinically significant).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Laboratory results</measure>
    <time_frame>Day -2(Randomization) to Day 8~12(Post-study visit) in single ascending dose or Day-3d to Day 22~ (Post-study visit)</time_frame>
    <description>Hematology, Blood chemistry, Coagulation and Urinalysis were tested. The Average, Median, Standard Deviation, Min, Max values will be calculated to assess the safety/tolerability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum concentration of DWP16001</measure>
    <time_frame>0 hour (pre-dose), 0.25 hour, 0.5 hour, 0.75 hour, 1 hour, 1.5 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12hour, 24 hour, 36 hour, 48 hour, 72 hour</time_frame>
    <description>in single ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss: Maximum concentration of DWP16001 at steady state</measure>
    <time_frame>Day1 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour, Day 4, 7, 10, 13 0 hour (pre dose), Day 15 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour</time_frame>
    <description>in multiple ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss: Minimum concentration of DWP16001 at steady state</measure>
    <time_frame>Day1 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour, Day 4, 7, 10, 13 0 hour (pre dose), Day 15 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour</time_frame>
    <description>in multiple ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum concentration</measure>
    <time_frame>0 hour (pre-dose), 0.25 hour, 0.5 hour, 0.75 hour, 1 hour, 1.5 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12hour, 24 hour, 36 hour, 48 hour, 72 hour</time_frame>
    <description>in single ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss: Time of maximum concentration at steady state</measure>
    <time_frame>Day1 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour, Day 4, 7, 10, 13 0 hour (pre dose), Day 15 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour</time_frame>
    <description>in multiple ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast: Area under the plasma concentration-time curve from time 0 to 72hours</measure>
    <time_frame>0 hour (pre-dose), 0.25 hour, 0.5 hour, 0.75 hour, 1 hour, 1.5 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12hour, 24 hour, 36 hour, 48 hour, 72 hour</time_frame>
    <description>in single ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf: Area under the plasma concentration-time curve from time 0 to infinity</measure>
    <time_frame>0 hour (pre-dose), 0.25 hour, 0.5 hour, 0.75 hour, 1 hour, 1.5 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12hour, 24 hour, 36 hour, 48 hour, 72 hour</time_frame>
    <description>in single ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau: Area under the plasma concentration-time curve from time 0 to tau(dosing interval)</measure>
    <time_frame>Day1 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour, Day 4, 7, 10, 13 0 hour (pre dose), Day 15 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour</time_frame>
    <description>in multiple ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2: Elimination half-life</measure>
    <time_frame>0 hour (pre-dose), 0.25 hour, 0.5 hour, 0.75 hour, 1 hour, 1.5 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12hour, 24 hour, 36 hour, 48 hour, 72 hour</time_frame>
    <description>in single ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2: Elimination half-life</measure>
    <time_frame>Day1 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour, Day 4, 7, 10, 13 0 hour (pre dose), Day 15 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour</time_frame>
    <description>in multiple ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of serum glucose</measure>
    <time_frame>0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour</time_frame>
    <description>in single ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of serum glucose</measure>
    <time_frame>Day 1 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour, Day 4, 7, 10, 13 pre dose, Day 15 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour</time_frame>
    <description>in multiple ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of insulin</measure>
    <time_frame>Day -1 pre dose, 0.5, 1, 1.5, 2, 3, 4 hour, Day 15 pre dose, 0.5, 1, 1.5, 2, 3, 4 hour</time_frame>
    <description>in multiple ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline for Body weight in kilograms</measure>
    <time_frame>Day -1 0 hour, Day 15 0 hour</time_frame>
    <description>in multiple ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline for HbA1C in percent</measure>
    <time_frame>Day -1 0 hour, Day 15 0 hour</time_frame>
    <description>in multiple ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of Urine glucose excretion</measure>
    <time_frame>0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour</time_frame>
    <description>in single ascending dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of Urine glucose excretion</measure>
    <time_frame>Day 1 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour, Day 4, 7, 10, 13 pre dose, Day 15 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour</time_frame>
    <description>in multiple ascending dose cohort</description>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1: DWP16001 Amg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP16001 Amg, tablets, orally, single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: DWP16001 Bmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP16001 Bmg, tablets, orally, single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: DWP16001 Cmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP16001 Cmg, tablets, orally, single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: DWP16001 Dmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP16001 Dmg, tablets, orally, single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: DWP16001 Emg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP16001 Emg, tablets, orally, single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: DWP16001 Fmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP16001 Fmg, tablets, orally, single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1-6: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1-6: Dapagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Forxiga® tablets, orally, single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7: DWP16001 Gmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP16001 Gmg, tablets, orally, single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8: DWP16001 Hmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP16001 Hmg, tablets, orally, single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9: DWP16001 Img</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP16001 Img, tablets, orally, single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7-9: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7-9: Dapagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Forxiga® tablets, orally, repeated dose administration(for 15days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP16001</intervention_name>
    <description>DWP16001 tablets</description>
    <arm_group_label>Cohort 1: DWP16001 Amg</arm_group_label>
    <arm_group_label>Cohort 2: DWP16001 Bmg</arm_group_label>
    <arm_group_label>Cohort 3: DWP16001 Cmg</arm_group_label>
    <arm_group_label>Cohort 4: DWP16001 Dmg</arm_group_label>
    <arm_group_label>Cohort 5: DWP16001 Emg</arm_group_label>
    <arm_group_label>Cohort 6: DWP16001 Fmg</arm_group_label>
    <arm_group_label>Cohort 7: DWP16001 Gmg</arm_group_label>
    <arm_group_label>Cohort 8: DWP16001 Hmg</arm_group_label>
    <arm_group_label>Cohort 9: DWP16001 Img</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>DWP16001 placebo-matching tablets, Active control placebo-matching tablets</description>
    <arm_group_label>Cohort 1: DWP16001 Amg</arm_group_label>
    <arm_group_label>Cohort 2: DWP16001 Bmg</arm_group_label>
    <arm_group_label>Cohort 3: DWP16001 Cmg</arm_group_label>
    <arm_group_label>Cohort 4: DWP16001 Dmg</arm_group_label>
    <arm_group_label>Cohort 5: DWP16001 Emg</arm_group_label>
    <arm_group_label>Cohort 6: DWP16001 Fmg</arm_group_label>
    <arm_group_label>Cohort 1-6: Placebo</arm_group_label>
    <arm_group_label>Cohort 1-6: Dapagliflozin</arm_group_label>
    <arm_group_label>Cohort 7: DWP16001 Gmg</arm_group_label>
    <arm_group_label>Cohort 8: DWP16001 Hmg</arm_group_label>
    <arm_group_label>Cohort 9: DWP16001 Img</arm_group_label>
    <arm_group_label>Cohort 7-9: Placebo</arm_group_label>
    <arm_group_label>Cohort 7-9: Dapagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Forxiga®</description>
    <arm_group_label>Cohort 1-6: Dapagliflozin</arm_group_label>
    <arm_group_label>Cohort 7-9: Dapagliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male adults aged 19 to 50 at the time of screening test.

          2. Body weight between 50.0 kg and 90.0 kg and Body Mass Index (BMI) between 18.0 and
             27.0.

          3. Written consent on voluntary decision of participation prior to the screening
             procedure after being fully informed of and completely understanding this study.

          4. Eligible to participate in the study by discretion of the investigator following
             medical examination by interview, physical examination, and clinical examination.

        Exclusion Criteria:

          1. Presence of a clinically significant hepatic, renal, nervous, respiratory, endocrine,
             blood•tumor, cardiovascular, urogenital, psychiatric disorder or prior history.

          2. Presence or prior history of a gastrointestinal disorder (e.g., gastrointestinal
             ulcers, gastritis, stomach cramps, gastroesophageal reflux disease, Crohn's disease,
             etc.), or prior history of surgery (except for simple appendectomy or hernia surgery)
             that may affect safety and PK/PD assessment.

          3. Hypersensitivity to a drug containing an ingredient of the investigational product
             (DWP16001), Dapagliflozin or similar ingredient or other drugs (e.g., aspirin,
             antibiotics, etc.) or medical history of clinically significant hypersensitivity.

          4. Following laboratory abnormalities identified during the screening test:

               -  AST (SGOT), ALT (SGPT) &gt;1.5 upper limit of normal range

               -  Creatinine clearance calculated by the MDRD equation &lt; 90 mL/min

               -  Repeatedly confirmed QTc interval &gt; 450 ms

               -  Fasting serum glucose &gt; 110mg/dL or &lt; 70mg/dL

               -  Serum HbA1c &gt; 6.5 mg/dL
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyung-Sang Yu, MD, PhD</last_name>
      <phone>82-2-2072-1920</phone>
      <email>ksyu@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2017</study_first_submitted>
  <study_first_submitted_qc>December 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2017</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

